Bexinib 5mg Tablet

Bexinib 5mg Tablet is a prescription drug. It can be taken with or without food. But better is to take it at a fixed time every day for getting better results.

Uses of Bexinib 5mg Tablet:

• Kidney cancer

How does a Bexinib 5mg Tablet work?

Axitinib is a selective inhibitor of the vascular endothelial growth factor receptor. It blocks the activity of VEGF which is critical to tumour growth and metastasis and inhibits angiogenesis or the development of new blood vessels.

How to Use & Dosage:

Administered through orally usually once every day. The tablets should be swallowed whole and not chewed or broken. They may be taken with or without food.

Your doctor will decide the dose and how long you should take Bexinib 5mg Tablet based on your condition. The usual initial dose is five milligrams twice a day. Do not take a double dose to make up for a missed dose. Take your next scheduled dose as usual.

Possible Side Effects:

• Fatigue
• Hot flashes
• Hypertension
• Diarrhea
• Dizziness
• Nausea
• Vomiting

Safety Advise:

🫀 Liver

Use Bexinib 5 mg tablet with caution in patients with severe liver disease. The dose of Bexinib 5 mg tablet may need to be changed. Please consult your healthcare provider.

🤰 Pregnancy

Bexinib 5 mg tablet is likely unsafe for use during pregnancy. Please talk to your healthcare provider.

🤱 Breast Feeding

Bexinib 5 mg tablet Information for Nursing Mothers. Lack of data can mean that it is not known whether Bexinib 5 mg tablets are safe to use while nursing. Please consult your healthcare provider.

🍺 Alcohol

It is not known whether it is safe to use Bexinib 5 mg tablets with alcohol. Please consult with your medical doctor.

🚗 Driving

Blood sugar that is too high or too low can affect how well you drive. If you have these symptoms, do not drive. Check with your healthcare provider.

Storage Instructions:

Store at room temperature. Keep out of reach of children. Keep away from heat and moisture.

References

1. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939.
2. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncology. 2013;14(6):552-562.
3. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education.
4. Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers.
5. Pfizer Inc. Inlyta (axitinib) tablets: prescribing information. New York, NY: Pfizer Inc.

Disclaimer:

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.